ClinicalTrials.gg
CompletedNCT05363293"MAD"Updated May 14, 2025Results posted

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

A Phase 1/2 interventional study of AL001 and Placebo in Alzheimer's Disease and Healthy Non-elderly and Elderly Adults, sponsored by Alzamend Neuro, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Alzamend Neuro, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
837th of 1,609
65 · median 73
Started
2022
with 130 others
Phase 1/2
67 of 1,940
17 open now
Registered
1,448th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 837th largest by enrollment of the 1,609 interventional ones that give a count, is one of 131 that started in 2022, is one of 67 in phase 1/2, and was the 1,448th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.

Read the detailed description

This is a Phase 1/2a, multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose (MTD) of AL001, a crystal engineered lithium-salicylate-proline lithium delivery product that in nonclinical studies was shown to enhance and prolong the pharmacokinetic (PK) profile of lithium in the brain with enhanced efficacy potential in Alzheimer's models compared to lithium carbonate.

A maximum of approximately 72 participants will be enrolled. Participants will be randomly assigned to receive study drug (active AL001) or placebo in a ratio of 6:2, respectively, with 8 patients in each dosing cohort. Placebos will be pooled and regarded as a comparative cohort for safety.

Cohorts 2a, 3a, 4a and 5a will involve 1:1 healthy non-elderly and elderly subjects; cohorts 1, 2b, 3b, 4b and 5b will involve Alzheimer's subjects. The study will consist of a screening period (Days -28 to -2), a 14-day treatment period, and a 42-day follow-up period.

03

Conditions studied

  • Alzheimer's Disease
  • Healthy Non-elderly and Elderly Adults

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Alzheimer's Patients):

  • Mild to moderate Alzheimer's disease (reasonably good physical health per Investigator's review of medical \& surgical history, physical examination incl. neurological examination, 12-lead , vital signs, and clinical laboratory tests)
  • Able to understand and provide written and able to understand and follow instructions during study as determined by Investigator
  • Subject and caregiver (if accompanying subject on site) willing to follow study procedures, willing \& able to adhere to study restrictions and to be confined at the clinical research center for 16 days
  • Fluent in English speaking, reading, and writing (for cognitive testing)
  • Availability of medical history to provide information about the cognitive and functional level of the participant and of a qualified source such as the caregiver willing and able to provide information about the cognitive and functional level of the participant
  • Males (non-vasectomized and vasectomized) must agree to use barrier during the study until after Study Day 42
  • Females must meet criteria if childbearing for contraception or be non-childbearing
  • Clinical diagnosis of dementia (neurocognitive disorder) by a qualified clinician based on the criteria
  • Considered AD Stage 2, 3, or 4 based on the FDA classification
  • (MMSE) score between 16 and 26, inclusive, at Screening
  • Negative result to COVID-19 test at Screening and admission (performed on Day -1)

Exclusion Criteria (Alzheimer's Patients):

  • abnormalities (as determined by investigator based on medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings) that may affect subject safety or successful study participation
  • Presence or history of any disorder that may prevent the successful completion of the study
  • Other severe acute, chronic, or historical medical or psychiatric condition or laboratory abnormality or social circumstance that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in judgment of the Investigator, would make the subject inappropriate for entry into this study
  • Evidence of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, dermatologic, muscular, or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) that may affect the safety or successful participant of the subject
  • Any history or presence of gastrointestinal disease including chronic gastritis, hemorrhagic gastritis, peptic ulcers, duodenitis, diarrhea, or inflammatory bowel disease
  • Any presence or history of acute or chronic liver diseases
  • Any post-surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study treatment
  • Any history of frequent headache or migraine
  • Kidney disease ( \<60 mL/minute/1.73 m2)
  • Uncontrolled tachy/brady arrhythmias, atrial fibrillation, or coronary heart failure
  • Psychiatric or neurological illnesses (other than Alzheimer's disease), e.g., schizophrenia or other psychotic syndromes, Parkinson's disease and related movement disorders, myasthenia gravis, and seizure disorder/history of seizure disorder and/or severe head trauma (other than a single childhood febrile seizure)
  • Presence of depression, except for mild depression with no acute episodes and stable condition, as determined by the Investigator
  • History of untreated thyroid dysfunction that may be independently associated with cognitive impairment
  • Central nervous system-related exclusions:

    1. any medical condition that (per investigator's judgement) would affect subject safety and scientific integrity of the study, e.g., untreated hypothyroidism (TSH >10 mIU/L) or vitamin B12 deficiency (\<300 pg/mL) which may contribute to cognitive impairment, delirium, non-AD dementia and other encephalopathies
    2. Hachinski scale score >4 or evidence of stroke within the past 5 years
  • Systemic related exclusions:

    1. Active cancer (except squamous cell and basal skin cancers) requiring chemo- or radiation therapy
    2. Positive test results for , , and (unless quantitative PCR negative for HCV) at Screening
    3. Uncontrolled hypertension with a sustained blood pressure >160/100 mmHg at Screening, check-in (Day -1), and prior to the first study drug administration
    4. Fever (body temperature >101.4°F [38.5°C]), acute upper respiratory, or any other infections at Screening, check-in (Day -1), and prior to the first study drug administration
  • Any history of drug , asthma (with the exception of childhood asthma), urticaria or other severe allergic diathesis
  • History of adverse - or hypersensitivity reaction to lithium, aspirin, salicylate, L-proline, or any test article
  • Female who is breastfeeding, pregnant according to the pregnancy test at Screening or prior to the first study drug administration, or planning to become pregnant during the study
  • Magnetic resonance imaging (MRI)-related exclusion criteria (such as intracranial mass, evidence or other anatomical findings that might affect safety or causes of cognitive impairment as assessed by a qualified neurologist)
  • History of drug abuse (barbiturate, amphetamine, benzodiazepine, cocaine, opiates and cannabis) within the last 12 months or a positive urine drug screen at Screening or Day -1
  • Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements or positive alcohol test at Screening or Day -1.
  • More than moderate current alcohol consumption (subjects will be advised to consume no more than 2 units of alcohol/d and completely abstain from 72 hours prior to any visit.
  • Treatment with haloperidol, antipsychotics, monoamine oxidase inhibitors, or neuromuscular blocking agents. An appropriate drug-free period will be required for washout, particularly for any especially long half-life drugs.
  • Hyponatremia, defined as serum sodium laboratory value outside the standard reference range
  • Suspected of having or at risk for Brugada Syndrome
  • Prescribed or OTC use of a salicylate-containing product other than low-dose aspirin for cardioprotection (e.g., aspirin, bismuth sub-salicylate, salicylazosulfapyridine [sulfasalazine]) from 1 week before first dose to 1 week after last dosing; any other prescribed anticoagulant medication
  • Consumption of poppy seeds or quinine (tonic water) 48 hours prior to Day 1
  • Aspirin/nasal polyposis/asthma syndrome
  • Participation in a clinical trial and receipt of an investigational medication within 30 days or 5 half-lives (if known), whichever is greater, prior to the first dose of the current study drug.

Inclusion criteria (Healthy Subjects):

  • Non-elderly (≥18 and \<65 years) and elderly (≥65 and ≤80 years) male and/or female adult subjects of any gender, race or ethnicity, determined to be generally in good physical health
  • Willingness to use contraceptive methods as appropriate

Exclusion criteria (Healthy Subjects)

  • Clinically significant abnormalities detected by medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings or any historical or present condition/ treatment that may prevent successful or safe study completion, including substance abuse, kidney disease (estimated glomerular filtration rate [eGFR] \<60 mL/minute/1.73 m2) or hyponatremia
  • Use of any medication on a chronic basis except an oral contraceptive, with appropriate of prescription, OTC, vitamins and herbal supplements
  • Female pregnant or planning to be pregnant, or breastfeeding
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1

    Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort. A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits. Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo: • Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2a

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID).

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2b

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID).

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)

    Drug: AL001 · Other: Placebo

  • Experimental
    Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b

    The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID).

    Drug: AL001 · Other: Placebo

Interventions

  • DrugAL001

    a crystal engineered lithium-salicylate-proline lithium delivery product

    Also known as: Alzamend AL001

  • OtherPlacebo

    matching placebo formulation

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.

    To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following: Proportion of participants with treatment-emergent adverse events (TEAEs) * Proportion of participants with serious AEs * Proportion of participants with TEAEs that lead to premature discontinuation * Proportion of participants with abnormal values for each safety laboratory test (change from baseline) * Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters) For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.

    Time frame: 42 days with a 14-day treatment period

Secondary outcomes

  1. Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001

    To characterize the MTD of AL001 in all subjects treated with AL001: • Proportion of subjects in each Cohort with plasma trough measurements of lithium \> 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.

    Time frame: 42 days with a 14-day treatment period

  2. Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects

    To characterize the MTD of AL001 in all subjects: • Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate \> 30 mg/dL

    Time frame: 42 days with a 14-day treatment period

07

Results

Posted May 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneMultiple Ascending Doses of AL001 - Cohort 1Multiple Ascending Doses of AL001 - Cohort 2aMultiple Ascending Doses of AL001 - Cohort 2bMultiple Ascending Doses of AL001 - Cohort 3aMultiple Ascending Doses of AL001 - Cohort 3bMultiple Ascending Doses of AL001 - Cohort 4aMultiple Ascending Doses of AL001 - Cohort 4bMultiple Ascending Doses of AL001 - Cohort 5aMultiple Ascending Doses of AL001 - Cohort 5bCombined Placebo Group
Started76666666016
Completed66666666016
Not completed1000000000
Withdrew: Withdrawal by subject1000000000

Outcome measures

PrimaryNumber of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.

To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following: Proportion of participants with treatment-emergent adverse events (TEAEs) * Proportion of participants with serious AEs * Proportion of participants with TEAEs that lead to premature discontinuation * Proportion of participants with abnormal values for each safety laboratory test (change from baseline) * Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters) For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.

Time frame:
42 days with a 14-day treatment period
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.
ParticipantsMultiple Ascending Doses of AL001 vs. Placebo - Cohort 1Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2aMultiple Ascending Doses of AL001 vs. Placebo - Cohort 2bMultiple Ascending Doses of AL001 vs. Placebo - Cohort 3aMultiple Ascending Doses of AL001 vs. Placebo - Cohort 3bMultiple Ascending Doses of AL001 vs. Placebo - Cohort 4aMultiple Ascending Doses of AL001 vs. Placebo - Cohort 4bMultiple Ascending Doses of AL001 vs. Placebo - Cohort 5aMultiple Ascending Doses of AL001 vs. Placebo - Cohort 5bMultiple Ascending Doses of AL001 - Pooled Placebo Group
Serious AEs0000000000
TEAEs that lead to premature discontinuation00000000—0
Abnormal values for safety laboratory tests (change from baseline)00010100—0
abnormal ECG parameters (change from baseline)00000000—0
No Adverse Events observed66656566—16
SecondaryMaximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001

To characterize the MTD of AL001 in all subjects treated with AL001: • Proportion of subjects in each Cohort with plasma trough measurements of lithium \> 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.

Time frame:
42 days with a 14-day treatment period
Reported as:
Number · Proportion of Subjects
Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001
Proportion of SubjectsMultiple Ascending Doses of AL001 in AD Subjects - Cohort 1Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 2bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 3bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 4bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 5bMultiple Ascending Doses of AL001 - Pooled Placebo Group
Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL00100000000.167—0
SecondaryMaximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects

To characterize the MTD of AL001 in all subjects: • Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate \> 30 mg/dL

Time frame:
42 days with a 14-day treatment period
Reported as:
Number · Proportion of Subjects
Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects
Proportion of SubjectsMultiple Ascending Doses of AL001 in AD Subjects - Cohort 1Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 2bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 3bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4aMultiple Ascending Doses of AL001 in AD Subjects - Cohort 4bMultiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5aMultiple Ascending Doses of AL001 - Pooled Placebo Group
Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects00000000.1670

Adverse events

Collected over 42 days with a 14 day treatment period per cohort (phone call follow-up on day 42 to confirm safety). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AD in Cohort 10/6 (0%)0/6 (0%)0/6 (0%)
AD on Cohort 20/6 (0%)0/6 (0%)0/6 (0%)
AD in Cohort 30/6 (0%)0/6 (0%)5/6 (83.3%)
AD in Cohort 40/6 (0%)0/6 (0%)5/6 (83.3%)
Healthy Subjects in Cohort 20/6 (0%)0/6 (0%)3/6 (50%)
Healthy Subjects in Cohort 30/6 (0%)0/6 (0%)5/6 (83.3%)
Healthy Subjects in Cohort 40/6 (0%)0/6 (0%)3/6 (50%)
Healthy Subjects in Cohort 50/6 (0%)0/6 (0%)5/6 (83.3%)
AD Subjects on Placebo0/8 (0%)0/8 (0%)4/8 (50%)
Healthy Subjects on Placebo0/8 (0%)0/8 (0%)5/8 (62.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAD in Cohort 1AD on Cohort 2AD in Cohort 3AD in Cohort 4Healthy Subjects in Cohort 2Healthy Subjects in Cohort 3Healthy Subjects in Cohort 4Healthy Subjects in Cohort 5AD Subjects on PlaceboHealthy Subjects on Placebo
GastrointestinalGastrointestinal disorders0/60/62/62/62/64/62/64/60/83/8
InvestigationsInvestigations0/60/60/60/60/61/63/63/61/80/8
Nervous SystemNervous system disorders0/60/62/61/61/62/61/62/61/81/8
RespiratoryRespiratory, thoracic and mediastinal disorders0/60/60/60/61/60/61/62/60/80/8
PsychiatricPsychiatric disorders0/60/60/60/60/61/60/62/60/81/8
SkinSkin and subcutaneous tissue disorders0/60/60/60/61/61/61/61/61/82/8
Renal and UrinaryRenal and urinary disorders0/60/61/61/60/60/61/60/61/80/8
Procedural complicationsInjury, poisoning and procedural complications0/60/60/61/60/61/61/60/60/81/8
MusculoskeletalMusculoskeletal and connective tissue disorders0/60/60/60/61/60/60/60/60/81/8
Ear LabyrinthEar and labyrinth disorders0/60/60/60/60/60/60/61/60/80/8

Baseline characteristics

Cohort 1 (AD subject), n=6 randomized to AL001(1 withdrawal before dosing). Cohort 2a (healthy volunteers \[HV\]): n=6 rand. to AL001. Cohort 2b (AD): n=6 rand. to AL001. Cohort 3a (HV): n=6 rand. to AL001. Cohort 3b (AD): n=6 rand. to AL001. Cohort 4a (HV): n=6 rand. to AL001. Cohort 4b (AD): n=6 rand. to AL001. Cohort 5 (HV), n=6 rand. to AL001. Combined Placebo Group, n=16.

Age, Customized
Age, Customized(years)Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days)Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days)Combined Placebo GroupTotal
Mean63.1 (56 to 71)65.4 (52 to 77)65.4 (52 to 77)57.5 (24 to 72)57.5 (24 to 72)58.8 (32 to 74)58.8 (32 to 74)57.3 (33 to 70)—59.4 (24 to 75)60.2 (24 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days)Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days)Combined Placebo GroupTotal
Female04514242—1234
Male72152424—431
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days)Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days)Combined Placebo GroupTotal
American Indian or Alaska Native00000000—00
Asian00000000—00
Native Hawaiian or Other Pacific Islander00000000—00
Black or African American60424050—728
White16242616—937
More than one race00000000—00
Unknown or Not Reported00000000—00
Ratio of Plasma Lithium trough >1.0mEq/L or plasma salicylate peak concentrations >30mg/dL
Ratio of Plasma Lithium trough >1.0mEq/L or plasma salicylate peak concentrations >30mg/dL(ratio)Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID ×14 Days)Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID × 14 Days)Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID × 14 Days)Combined Placebo GroupTotal
Number00000000—00
08

Study locations

2 sites
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • Altasciences
    Mount-Royal, Quebec H3P 3P1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Apr 2023, 11 months.

Results were first posted in May 2025, 2 years 1 month after primary completion.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 5, 2022
StartActual
May 4, 2022
Primary completionActual
Apr 14, 2023
CompletionActual
May 15, 2023
Results first posted
May 14, 2025
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05363293
Lead sponsor
Alzamend Neuro, Inc.
Responsible party
Sponsor
First posted
May 5, 2022
Start date
May 4, 2022
Primary completion
Apr 14, 2023
Completion
May 15, 2023
Results posted
May 14, 2025
Last update
May 14, 2025

Study contacts

Eric Sicard, MD
principal investigator · Alzamend

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion